Use of biologics in rheumatoid arthritis: Where are we going?
- 15 September 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 63 (18_Supplem), S19-S41
- https://doi.org/10.2146/ajhp060365
Abstract
Purpose. The pharmacology, efficacy, safety, and costs of biologic agents that are approved by the Food and Drug Administration or are under review for the management of rheumatoid arthritis (RA) are discussed. Biologic therapies that are currently under investigation in early- and late-phase clinical trials are summarized at the end of this report.Keywords
This publication has 100 references indexed in Scilit:
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJama-Journal Of The American Medical Association, 2006
- Emerging biologic drugs for the treatment of rheumatoid arthritisAutoimmunity Reviews, 2005
- Cardiovascular death in rheumatoid arthritis: A population‐based studyArthritis & Rheumatism, 2005
- Capability for daily activities in old people with rheumatoid arthritis: a population based studyAnnals Of The Rheumatic Diseases, 2005
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisThe American Journal of Gastroenterology, 2004
- Rheumatoid arthritis therapy after tumor necrosis factor and interleukin‐1 blockadeArthritis & Rheumatism, 2003
- Control of rheumatoid arthritis by oral toleranceArthritis & Rheumatism, 2001
- Infliximab treatment and pregnancy outcome in active Crohn's diseaseThe American Journal of Gastroenterology, 2001
- Interpretation of cost-effectiveness analysesJournal of General Internal Medicine, 1998
- Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographsArthritis & Rheumatism, 1998